Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
GD Julian, S Maurer Mathew, H Falk Rodney… - …, 2016 - sfera.unife.it
Background-Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Non-Biopsy Diagnosis of Cardiac Transthyretin Amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini… - Circulation, 2016 - discovery.ucl.ac.uk
Background: Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy… - CIRCULATION, 2016 - iris.unipv.it
Background-Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy… - Circulation, 2016 - research.rug.nl
Background-Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy… - Circulation, 2016 - europepmc.org
Background Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy… - 2016 - Am Heart Assoc
Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
[PDF][PDF] Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy… - 2016 - researchgate.net
Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini… - …, 2016 - mayoclinic.elsevierpure.com
Background-Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …
cardiomyopathy for which several promising therapies are in development. The diagnosis is …